Advancing Alopecia Areata Treatment: A Look at the FDA Approval of Barcitinib

Host: Matthew S. Keller MD Guest: Natasha Mesinkovska, MD, PhD Alopecia areata affects more than 300,000 people in the United States each year, causing hair loss to the scalp, eyebrows, and eyelashes. But recent studies have shown that the Janus kinase inhibitor drug baricitinib can help significantly regrow hair for patients. To find out more about what this first-ever FDA approval of a systemic treatment could mean for patients with alopecia areata, Dr. Matthew Keller speaks with Dr. Natasha Mesinkovska, Associate Professor of Dermatology and Vice Chair for Clinical Research of Dermatology at University of California Irvine.

There are no comments yet.

Please log in to write the first comment.